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1. Introduction 
Essential hypertension (EH), which in general increases the arterial blood pressure, is a 
major health concern and risk factor for other diseases such as myocardial infarction and 
kidney failure (Barri, 2006; Stokes et al., 1989; Mosterd et al., 1999). EH development is 
known to be multifactorial, with both genetic determinants, such as allelic variation in the 
genes that are involved in renal salt absorption, and environmental factors that involve the 
diet (Lifton et al., 2001). The two widely recognized hallmarks of EH are resistance artery 
narrowing and large artery stiffening, which increase peripheral resistance and compromise 
vascular compliance, respectively. Both are known to contribute to the progression and 
cardiovascular morbidity and mortality associated with EH. However, despite decades of 
study, the initial causes that lead to these vascular abnormalities have yet to be completely 
elucidated. Moreover, the question remains as to whether these abnormalities exist prior to, 
and thus participate in, the initial phase of blood pressure elevation, or are a consequence  
of it. 
The extracellular matrix (ECM) in the vascular wall has been found to be a critical 
determinant, and therefore it is thought that EH is associated with both an increased 
cardiovascular deposition and an increased systemic turnover of ECM proteins (Diez et al., 
1995). Thus, vessel compliance dictated by the ECM is also involved in modulating the 
blood pressure. 
Transforming growth factor (TGF)-β1 is an extracellular polypeptide member of the TGF-β 
superfamily of cytokines. It is a secreted protein that performs many cellular functions 
including control of cell growth, cell proliferation, cell differentiation and apoptosis. TGF-β1 
acts bifunctionally to elevate blood pressure by first altering levels of vasoactive mediators 
and then by changing the vessel wall architecture to increase the peripheral resistance. In 
the cardiovascular system, TGF-β1 may play a key role in the regulation of the mechanical 
strain-induced matrix synthesis by the human vascular smooth muscle (VSM) cells. If so, 
this suggests that TGF-β1 may also play an important role in the development of 
hypertension-induced cardiovascular fibrosis (O'Callaghan&Williams, 2000). 
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Elastin microfibril interface-located protein 1 (EMILIN1) is a glycoprotein expressed in the 
vascular tree that binds to the TGF-β1 precursor and prevents processing by furin. Emilin 1 
knockout mice display increased TGF-β1 signaling in their vessel walls. These animals 
develop peripheral vasoconstriction and arterial hypertension, which can be prevented by 
inactivation of one TGFB1 allele (Zacchigna, et al., 2006). These matrix-dependent changes in 
the vascular hemodynamics caused by TGF-β1 and EMILIN1 are important because they 
ultimately affect the cardiovascular morbidity and mortality rates. 
This brief review focuses on the important roles of TGF-β1 and EMILIN1 in human 
hypertension, and in addition, evaluates the available data within the context of the current 
knowledge that has been collected from animal models of this disease. 
2. Transforming growth factor-β1 
2.1 The family of TGFs 
The family of transforming growth factor (TGF) β belongs to a superfamily that consists of 
over 25 diverse dimeric extracellular polypeptides of 110-140 amino acids. These 
polypeptides include bone morphogenetic proteins, activins, and inhibitors (Massague et al., 
1994). After discovery of the initial member of the TGF family in 1980 (Roberts et al., 1980), 
these important molecules have subsequently been shown to have complex effects on organ 
development, cell growth and differentiation. However, they are particularly important 
with regard to the expression of ECM proteins. There are three cytokine isoforms of TGF-β 
in mammals, TGF-β1, TGF-β2, and TGF-β3. All of these isoforms bind to the same receptors. 
In addition, they are encoded by separate genes sharing 60-80% homology and thus are 
most likely derived from a common ancestor. The major difference between the isoforms 
appears to be the spatiotemporal control of their expression patterns. While in vitro TGF-β 
isoforms have a similar effect on biologic tissues, they are generally characterized in vivo by 
varied degrees of expression and different functions. Their biologic activity depends on 
quantitative relationships between the individual isoforms (Cho et al., 2004; Li et al., 1999; 
Nakamura et al., 2004). 
2.2 TGF-β1 in human hypertension 
TGF-β1 is recognized as the most pivotal TGF-β isoform for the cardiovascular system, as it 
is present in VSM cells, endothelial cells, myofibroblasts, macrophages, and other 
hematopoietic cells (Annes et al., 2003). TGF-β1 strongly up-regulates the production of 
ECM proteins including fibronectin and collagen (Ignotz&Massague, 1986), and inhibits the 
degradation of the ECM by tissue proteinases (Laiho&Keski-Oja, 1989). Although TGF-β1 
acts in wound healing via its effects on the ECM, excessive TGF-β can cause several fibrotic 
diseases including glomerulonephritis and diabetic nephropathy (Okuda et al., 1990). While 
TGF-β1 has long been thought to have only paracrine and autocrine effects, it has now been 
shown to have wide-ranging systemic (endocrine) effects (Sporn, 1997). 
Lin et al. examined the association between serum TGF-β1 levels and gender, age, and 
selected lifestyle factors in a large number of healthy Japanese control subjects (Lin et al., 
2009). They found that serum TGF-β1 levels appear to be modulated in part by gender, age 
and lifestyle factors such as obesity, cigarette smoking, and alcohol drinking (Lin et al., 
2009). Overproduction of TGF-β1 clearly underlies the tissue fibrosis noted in numerous 
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experimental and human diseases, including EH. Li et al. demonstrated for the first time 
that a positive correlation exists between circulating TGF-β1 levels and blood pressure in 
humans (Li et al., 1999). In another previous study, they also reported that the TGF-β1 
protein concentration in hypertensive subjects (n=61) was 261±9 ng/ml as compared to 
188±7 ng/ml in normotensive controls (n=90) (P<0.0001) (Suthanthiran et al., 2000). Obesity 
is an independent risk factor for EH and cardiovascular diseases. A strong relationship 
exists between the body mass index and blood pressure. Porreca et al. have reported that 
TGF-β1 levels are independently associated with obesity in hypertensive patients (Porreca et 
al., 2002). In addition, TGF-β1 is positively correlated with the body mass index and 
creatinine clearance in EH patients (Torun et al., 2007). In adipose tissue from both obese 
mice and humans, the levels of tissue TGF-β1 antigen have been shown to be well correlated 
with BMI (Alessi et al., 2000). Moreover, the TGF-β1 gene was reported to be associated with 
obesity phenotypes such as BMI, fat mass, and lean mass in a large Caucasian population 
sample (Long et al., 2003). Likewise, an association was also observed between the TGF-β1 
polymorphism and both the BMI and abdominal obesity in Swedish men (Rosmond et al., 
2003). These data suggest that elevated levels are not just simply a marker of a similar 
disease production mechanism, but in fact indicate that elevated levels of circulating TGF-β1 
lead to disease production and to the synergy of risk factors that are seen during EH 
production. 
2.3 The synthesis of TGF-β1 
TGF-β1 is synthesized by many cell types, including the endothelium, and is secreted as a 
latent dimeric ~75-kDa protein complex. While the enzyme furin cleaves a latency-
associated peptide from the active TGF-β molecule during intracellular processing, it 
remains noncovalently complexed to the mature peptide after secretion. In addition, latent 
TGF-β-binding proteins, which are members of the fibrillin/latent TGF-β-binding protein 
family, bind to this complex and then direct it to the adjacent interstitium. Once in the 
extracellular space, removal of the latent TGF-β frees the mature, ~24-kDa biologically active 
form of TGF-β (Annes et al., 2003). Thus, endothelium-derived TGF-β1 is typically a locally 
acting molecule that has autocrine and paracrine actions on the neighboring endothelium 
and VSM. There are several known mechanisms of activation for TGF-β1. Thrombospondin-
1 is secreted by the endothelial cells and appears to be the major regulatory factor involved 
in this activation (Schultz-Cherry et al., 1994). However, other factors have been identified 
that stimulate TGF-β1. For example, increased vascular wall stress that occurs in 
hypertensive individuals can sufficiently promote a strain "dose-dependent" increase in the 
TGF-β1 production by VSM cells, which leads to an associated increase in the matrix 
accumulation (O'Callaghan&Williams, 2000). Norepinephrine (Briest et al., 2004), hypoxia 
(Lee et al., 2009), oxidative stress (Zhao et al., 2008) and high glucose levels (Iglesias-de la 
Cruz et al., 2002) have also been shown to induce TGF-β1 production. Most of the 
information known about TGF-β1 has been collected from in vitro and in vivo animal 
models. Since human TGF-β1 and its nonhuman counterparts share a sufficiently high 
degree of homology, this makes it possible to extrapolate relevant data from animals to 
humans. 
The Smad proteins (Smad2, Smad3 and Smad7) are essential components of the downstream 
TGF-β signaling. Positive signaling via activation of Smad2/3, along with negative signaling 
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via the negative feedback mechanism of Smad7, are able to regulate the biological activities 
of TGF-β1 (Kretzschmar&Massague, 1998). Activation of Smad3, but not Smad2, is one of 
the key and absolute necessary mechanisms required for Angiotensin (Ang) II-induced 
vascular fibrosis. This is because the Ang II-induced Smad3/4 promoter activities and 
collagen matrix expression are abolished in VSMCs null for Smad3 but not Smad2. There are 
several phases that promote Smad signaling in Ang II. During the first phase, Ang II directly 
activates an early Smad signaling pathway at approximately 15 to 30 minutes. During the 
second phase, Ang II subsequently activates the late Smad2/3 signaling pathway at 24 
hours. This pathway is TGF-β1 dependent, as it can be blocked by the anti-TGF-β antibody 
(Wang W et al., 2006). 
2.4 TGF-β1 and the renin-angiotensin system 
Ang II promotes sodium retention, cell growth and fibrosis, in addition to the classical 
effects it has on blood pressure and fluid homeostasis. Since it is well known that Ang II 
enhances TGF-β1 expression, TGF-β1 signaling pathways, and cardiac remodeling, which 
includes cardiac hypertrophy and cardiac fibrosis, the activation of TGF-β1 is considered to 
be closely associated with an Ang II excess (Ruiz-Ortega et al., 2007). 
In the hypertrophic myocardium, TGF-β1 tissue levels are markedly increased after cardiac 
stress loading, such as with an Ang II excess (Ikeda et al., 2005; Yagi et al., 2008). 
Furthermore, the stimulus that is associated with the increase in the activity of Ang II in 
heart tissue can repeatedly trigger the expression of TGF-β1 and lead to continual injury. 
Therefore, it is thought that there is a biologically rich and complex interaction that occurs 
between the renin-angiotensin system (RAS) and TGF-β1 in which both act at various points 
to regulate the actions of the other. This interaction might be the key to understanding the 
vital roles that RAS and TGF-β1 play in EH development. 
Another interplay between RAS and TGF-β1 involves the level of aldosterone. Ang II 
normally stimulates the production and release of aldosterone from the adrenal gland. 
Conversely, TGF-β1 suppresses production and strongly blocks the ability of Ang II to 
stimulate aldosterone by reducing the number of Ang II receptors expressed in the adrenal 
gland (Gupta et al., 1992). Furthermore, it has been shown that TGF-β1 can block the effects 
of aldosterone on sodium reabsorption in cultured renal collecting duct cells (Husted et al., 
1994). It has also been shown that after an infusion of aldosterone into rats with a remnant 
kidney, there is an increase in blood pressure, proteinuria, and glomerulosclerosis along 
with a neutralization of the beneficial effects of the Ang II blockade (Greene et al. 1996). 
Although the mechanism of aldosterone’s pathological effects is still unknown, it might be 
due to stimulation of TGF-β1 production in the kidney. 
EH is the most common cause of hypertension. The second most common cause of 
hypertension is primary aldosteronism (PA), which has recently been implicated in the 
alterations of the immune system and progression of cardiovascular disease. As compared 
to EH controls, PA patients have lower TGF-β1 levels (17.6+/-4.1 vs. 34.5+/-20.5 pg/ml, 
p<0.001). In addition, TGF-β1 levels were shown to exhibit a remarkable correlation with the 
serum-aldosterone/plasma-renin-activity ratio in the total group (PA+EH) (Carvajal et al., 
2009). Therefore, a chronic aldosterone excess in PA patients appears to modify the TGF-β1 
levels. If so, this could lead to an imbalance in the immune system homeostasis, thereby 
leading to an early proinflammatory cardiovascular phenotype in these patients. 
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2.5 TGF-β1 and endothelin 1 
Endothelin-1 (ET-1) is a vasoconstricting peptide that is produced primarily in the 
endothelium and which seems to play a key role in vascular homeostasis, tissue remodelling 
and fibrogenesis. These effects are mediated via two receptor types, ETA and ETB. In blood 
vessels, ETA receptors are found in VSM cells, whereas ETB receptors are mainly localized on 
endothelial cells and, to some extent, in VSM cells and macrophages. ET-1, which acts 
predominantly via the ETA receptors, promotes vasoconstriction, cell growth, adhesion, 
fibrosis, and thrombosis. TGF-β1 induces ET-1 expression by a functional cooperation 
between Smads and activator protein-1 via activation of the Smad signaling pathway (Yang 
et al., 2010). Moreover, TGF-β1 enhances NO generation in the endothelium, which in turn 
suppresses TGF-β1 production. When NO production is impaired, such as with 
hypertension, aging, and other systemic diseases, unopposed excess vascular TGF-β1 
production results in reduced vascular compliance and augmented peripheral arterial 
constriction and hypertension. Thus, NO functions as both a regulator for TGF-β1 
production and as a physiological antagonist of ET-1. 
Data from clinical trials have already demonstrated significant blood pressure lowering 
effects that occur after the combined use of ETA-ETB receptor blockers. ET-1 receptor 
blockade diminishes TGF-β production in cardiac, vascular, and renal tissues (Kowala et al., 
2004). While the role that ET-1 plays in normal cardiovascular homeostasis and in mild EH 
is still unclear, plasma ET-1 levels are increased in EH patients with atherosclerosis or 
nephrosclerosis when compared with patients with uncomplicated EH (Lariviere&Lebel, 
2003). Thus, targeting the endothelin system might potentially be an important therapeutic 
treatment for EH, particularly for preventing target organ damage and managing 
cardiovascular disease. 
2.6 TGF-β1 and organ damage-induced hypertension 
Several in vitro and in vivo studies have confirmed the role of TGF-β1 in the development of 
heart muscle hypertrophy. An in vivo model has demonstrated there is an increase in 
mRNA and protein levels of TGF-β1 in the cardiomyocytes of hypertrophied heart 
(Kobayashi et al., 2001). Overexpression of TGF-β1 in transgenic mice has been shown to 
result in cardiac hypertrophy that is characterized by both interstitial fibrosis and 
hypertrophic growth of the cardiomyocytes (Rosenkranz, et al., 2002). These findings 
indicate that local production of TGF-β1 in the hypertrophic myocardium and the link 
between the RAS and TGF-β1 signaling pathway are involved in the hypertrophic response. 
Hypertensive subjects can be considered to be at a higher risk of end-stage renal disease 
(ESRD). Scaglione et al. evaluated the relationship between circulating TGF-β1 and the 
progression of renal damage in a population of EH subjects. They evaluated the albumin 
excretion rate in EH patients and found there was a strong relationship between the 
progressive increase of TGF-β1 levels and the progression of renal damage (Scaglione et al., 
2002). Thus, it is possible that TGF-β1 overproduction may be the pathogenetic mechanism 
for the excess burden of hypertension and hypertensive renal damage. August et al. 
demonstrated that African Americans with ESRD had higher circulating levels of TGF-β1 
protein as compared to Caucasians with ESRD. They also found that hyperexpression of 
TGF-β1 was more frequent in African Americans with EH than in Caucasian Americans 
(August et al., 2000). Based on their findings, TGF-β1 is a treatment target that might be 
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especially pertinent in hypertensive African Americans. In addition, anti-TGF-β1 therapy 
could also be efficacious in preventing or slowing the progression of target organ damage. 
2.7 TGF-β1 gene polymorphisms, hypertension and organ damage 
The TGF-β1 gene, is located in the 19q13 chromosome and has 7 exons and 6 introns. 
Molecular biology research has confirmed that there are gene variations and 
polymorphisms in the TGFB1 that are associated with EH. A meta-analysis that was 
performed in the Chinese population and which included 5 separate studies with 2708 
subjects showed there was a relationship between the +869T/C polymorphism of TGFB1 
and EH. The pooled odds ratio (OR) for the CC/TC+TT genotype was 2.50, while the pooled 
OR for the frequency of the C allele was 1.43 (Yan-Yan, 2011). In Japanese individuals, 
Yamada et al. found that the frequency of the C allele in hypertensive women was higher 
than that seen in normotensive women, although there were no significant differences noted 
between hypertensive and normotensive men (Yamada et al., 2002). This research 
demonstrated that the association of the TGFB1 polymorphism and EH was most likely 
influenced by the gender factor. Another study suggested that the prevalence of the TC or 
CC genotypes of the +29T/C polymorphism in the gene was significantly higher in 
hypertensives versus normotensives. In addition, there was a higher prevalence of subjects 
with microalbuminuria and left ventricular hypertrophy (LVH) in hypertensives having 
these genotypes as compared to the hypertensives with the TT genotype (Argano et al., 
2008). 
To investigate the linkage between the TGFB1 polymorphism and the progression of 
atherosclerosis, Sie et al. conducted a population-based study that investigated five 
functional polymorphisms in TGFB1 (-800 G/A, -509 C/T, codon 10 Leu/Pro, codon 25 
Arg/Pro and codon 263 Thr/Ile) in relation to the arterial stiffness (pulse wave velocity 
(PWV), distensibility coefficient (DC) and pulse pressure (PP)). However, neither these 
polymorphisms nor the haplotypes were associated with the PWW, DC or PP (Sie et al., 
2007). Conversely, the C allele of TGFB1 rs4803455 in an elderly Chinese man was shown to 
be significantly associated with the prevalence of carotid plaque (Deng et al., 2011). 
As compared to Caucasian Americans, African Americans have a higher incidence and 
prevalence of hypertension and hypertension-associated target organ damage, which 
includes hypertensive nephrosclerosis. Suthanthiran et al. demonstrated that TGF-β1 
protein levels were the highest in African American hypertensives, and that the TGF-β1 
protein as well as the TGF-β1 mRNA levels were higher in hypertensives when compared to 
normotensives (Suthanthiran et al., 1998) They also showed that the proline allele at codon 
10 of TGFB1 was more frequently observed in African Americans as compared with 
Caucasian Americans. In addition, its presence was also associated with higher levels of 
TGF-β1 mRNA and protein. These findings suggest that TGF-β1 hyperexpression might be a 
risk factor for hypertension and hypertensive complications, in addition to being the basis of 
the mechanism for the excess burden of hypertension in African Americans. 
2.8 TGF-β1 and antihypertensive treatment 
Laviades et al. reported that the efficient blockade of the AT1 receptors that is observed 
when using losartan is associated with the inhibition of TGF-β1, normalization of collagen 
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type I metabolism, and reversal of left ventricular hypertrophy and microalbuminuria in 
hypertensive patients (Laviades et al., 2000). As a similar effect has been reported for 
captopril, this suggests that both angiotensin converting enzyme inhibitor (ACEI) and Ang 
II receptor blocker (ARB) attenuate the TGF-β1 expression (Sharma et al., 1999). 
Furthermore, although high glucose has also been shown to increase the production of Ang 
II and TGF-β1, both ACEI and ARB attenuated the increase in TGF-β1 production and 
reduced the cell proliferation caused by exposure to high glucose. These effects were greater 
when a combination of the two drugs were used (Kyuden et al., 2005). Scaglione et al. 
evaluated the effects of 24 weeks of losartan and ramipril treatment, both alone and in 
combination, on the circulating TGF-β1 and left ventricular mass (LVM) in EH patients. 
Their results showed that the absolute and percent reduction in TGF-β1 and LVM were 
significantly higher in the combined versus the individual losartan or ramipril groups. Thus, 
these findings indicate there is an additional cardioprotective effect provided by the dual 
blockade of renin-angiotensin in EH patients (Scaglione et al., 2007). 
Hallberg et al. determined the impact of the + 915G/C polymorphism of TGFB1 on the 
response to antihypertensive treatment. In a randomized double-blind study designed to 
treat EH patients for 48 weeks with either the AT1 receptor antagonist irbesartan or the β1-
adrenoceptor blocker atenolol, they examined the association between the TGF-β1 genotype 
and LVM regression in patients that had been echocardiographically diagnosed with LVH. 
Irbesartan-treated patients who were carriers of the C allele, which is associated with a low 
expression of TGF-β1, responded with a markedly greater decrease in the LVM index 
(LVMI) as compared to subjects with the GG genotype (adjusted mean change in LVMI -44.7 
g/m2 vs. -22.2 g/m2, p = 0.007). This decrease occurred independent of the blood pressure 
reduction. However, no association was noted between the genotype and the change in 
LVMI in the atenolol group. Therefore, they concluded that the TGF-β1 + 915G/C 
polymorphism was related to the change in the LVMI in response to the antihypertensive 
treatment with the AT1 receptor antagonist irbesartan (Hallberg et al., 2004). 
Based on these findings and the observations that ACEI and ARB are able to reduce Ang II-
mediated stimulation of the TGF-β1 production, treatments using these agents might be 
efficacious in preventing or slowing the progression of target organ damage in EH, 
especially in those patients who have LVH or hyperglycemia. Moreover, based on data 
presented above, it can be speculated that greater disease reduction could perhaps be 
achieved if TGF-β1 rather than blood pressure was the therapeutic target. 
3. Emilin 1 
3.1 EMILINs family 
EMILINs are a family of proteins of the extracellular matrix. The first protein of the family, 
initially named gp115, was isolated from chicken aorta under harsh solubilizing conditions. 
This protein was particularly abundant in the aortic tissue, and further 
immunohistochemical studies also showed it to be strongly expressed in blood vessels and 
in the connective tissues of a wide variety of organs, particularly in association with elastic 
fibers (Colombatti et al., 1987). At the ultrastructural level, the molecule was detected in 
elastic fibers, where it was located at the interface between the amorphous core and the 
surrounding microfibrils (Bressan et al., 1993). On the basis of this finding, the protein was 
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named EMILIN (elastin microfibril interface-located protein). Cloning of the cDNA of 
chicken EMILIN lead to the isolation in both human and mouse genes, with a total of three 
genes having been identified in humans and mice at the present time. The cardiovascular 
system has been demonstrated to be the major site of expression for the EMILIN genes 
(Braghetta et al., 2004). 
EMILINs share four protein domains, the C-terminal C1q domain, collagenous domain, 
coiled-coil domain and N-terminal cysteine-rich domain (EMI domain) (Colombatti et al., 
2000). There are also unique domains that are not shared by the EMILIN proteins. For 
example, EMILIN1 has two leucine zipper regions, multimerin has an endothelial growth 
factor-like domain, and EMILIN2 contains a proline-rich domain. This domain organization 
suggests that there are some shared and some specific functions for each of these EMILIN 
proteins. 
3.2 EMILIN1 and hypertension 
EMILIN1 was originally isolated form the aorta and is intimately associated with elastic 
fibers and microfibrils in the blood vessels, as well as in the connective tissue of other 
organs. EMILIN1 is a monomer when it is within the cells, but upon secretion, it 
oligomerizes via the formation of disulfide bonds. EMILIN1 appears to be more slowly 
secreted than other ECM components, although the implication of this is unclear 
(Colombatti et al., 2000). The function of EMILIN1 remained unknown until the gene was 
finally disrupted in mice. Although EMILIN1 knockout mice are fertile and have no obvious 
abnormalities, histological and ultrastructural examinations have shown there are 
alterations of the elastic fibers in the aorta and skin. Formation of elastic fibers by mutant 
embryonic fibroblasts in cultures has also been found to be abnormal (Zanetti et al., 2004). 
These mice develop larger lymphangiomas as compared to Wild type mice. Lymphatic 
vascular morphological alterations in these mice are also accompanied by functional defects, 
such as mild lymphedema, a highly significant drop in lymph drainage, and enhanced 
lymph leakage (Danussi et al., 2008). 
In 2006, Zacchigna et al. found that Emilin1 deficient mice become hypertensive (systolic 
blood pressure: 120±2 versus 101±1, n=46 per group, P<0.01), in addition to exhibiting an 
increased peripheral vascular resistance and a reduced vessel size, all of which were 
independent of the cardiac output. Strikingly, after inactivation of a single TGF-β allele, the 
high blood pressure in the mice returned to normal levels. A further study revealed that 
EMILIN1 inhibits TGF-β signaling by specifically binding to the proTGF-β precursor, 
thereby preventing its maturation by the furin convertases in the extracellular space 
(Zacchigna, et al., 2006). This study highlighted the importance of the relationship between 
EMILIN1 and TGF-β availability in the pathogenesis of hypertension. EMILIN1 may inhibit 
TGF-β by several different mechanisms. First, it is possible that it could interfere with TGF-β 
secretion or maturation, or second, it could prevent the presentation or the interaction of the 
TGF-β ligands with the cognate receptors. Finally, it could also be possible that it acts by 
sequestering either the immature or mature ligand (Zacchigna, et al., 2006). Therefore, 
further studies will need to be undertaken that conclusively prove that: 1) EMILIN1 
modulates TGF-β availability during the development of the cardiovascular system, 2) 
EMILIN1 is associated with the pathogenesis of hypertension, and 3) TGF-β maturation is 
linked to the blood pressure homeostasis that has been identified in animal studies. If these 
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future studies do lead to the discovery of the genetic susceptibility of EMILIN1 gene to 
hypertension, this will ultimately lead to a better understanding of the mechanism of human 
hypertension. 
3.3 EMILIN1 gene polymorphisms and EH 
The human EMILIN1 gene, which encodes EMILIN1, consists of 955 amino acids and is 
located on chromosome 2p23.3-p23.2, which overlaps with the promoter region of the 
ketohexokinase gene (Doliana et al., 2000). The gene is quite small and consists of 
approximately 7.3 kilo base-pairs that contain eight exons, and which are interrupted by 
seven introns. In a previous investigation of the association of the EMILIN1 gene 
polymorphisms and EH, we genotyped a total of 287 EH patients and 253 age-matched 
controls for five single-nucleotide polymorphisms (SNPs) used as genetic markers for the 
human EMILIN1 gene (rs2289408, rs2289360, rs2011616, rs2304682, and rs4665947). We 
confirmed that rs2289360, rs2011616, and rs2304682, as well as the haplotype constructed 
using rs2536512, rs2011616, and rs17881426 were useful genetic markers of EH in Japanese 
men (Shimodaira et al., 2010). In a Mongolian population, the rs2304682 locus in EMILIN1, 
as well as the haplotypes G-G constructed using rs3754734 and rs2304682, appeared to be 
associated with the susceptibility of EH. In addition, rs2304682 may also be associated with 
the level of the diastolic blood pressure (Mi et al., 2011). Conversely, Shen et al. reported 
finding no significant association between the EMILIN1 gene and EH, although the 
interaction of age and genotype variation of rs3754734 and rs2011616 might increase the risk 
of EH in the northern Han Chinese population (Shen et al., 2009). In order to definitively 
determine if there is an association between the genetic variation of the EMILIN1 gene and 
increases in the blood pressure, further studies that investigate the role of the EMILIN1 gene 
in vascular development and blood pressure homeostasis will need to be undertaken. At the 
present time, however, there have yet to be any reports of human hereditary diseases that 
are involved with EMILINs. Therefore, the morphological abnormalities revealed in this 
study constitute the first potential hallmark of EMILIN1 insufficiency, which may prove to 
be helpful in identifying heritable diseases induced by mutations of this gene in the future. 
4. Conclusion 
Many studies over the last decade have attempted to elucidate the important roles of TGF-
β1 and EMILIN1 in the maintenance of normal blood vessel wall architecture in humans. 
While most of the results reviewed here are consistent with the concept that TGF-β1 and 
EMILIN1 have similar roles in the vasculature of humans and rodents, direct and conclusive 
evidence has yet to be found. However, this is not all that surprising when one considers the 
difficulty of probing complex systems in humans. Although interventional experiments are 
commonplace in animal models, almost all without exception are impossible to perform in 
the regulatory systems in the human vasculature. From a therapeutic point of view, 
understanding the complexities of the interplay between the TGF-β1 signaling pathway and 
the development of EH are matters of great importance. For the most part, strategies that 
decrease TGF-β1 activity may very well be able to protect against hypertension and 
hypertensive organ damage. Once definitive information on the TGF-β1 signaling pathway 
and human hypertension becomes available, novel therapeutic approaches that modulate 
the biological actions of TGF-β1 might become available for use in EH patients. 
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